Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Down 27.1% in November

Capricor Therapeutics Inc (NASDAQ:CAPR) saw a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 3,850,000 shares, a decrease of 27.1% from the October 31st total of 5,280,000 shares. Based on an average trading volume of 3,160,000 shares, the short-interest ratio is currently 1.2 days.

Capricor Therapeutics Trading Down 0.2 %

Shares of CAPR traded down $0.03 during mid-day trading on Friday, reaching $19.01. The stock had a trading volume of 571,850 shares, compared to its average volume of 1,108,092. Capricor Therapeutics has a 52-week low of $2.90 and a 52-week high of $23.40. The business’s fifty day moving average is $18.03 and its 200 day moving average is $9.41.

Insiders Place Their Bets

In other news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the stock in a transaction that occurred on Friday, September 20th. The shares were bought at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the acquisition, the insider now owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. This represents a 65.21 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 12.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Main Street Financial Solutions LLC increased its holdings in shares of Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after buying an additional 7,500 shares during the last quarter. SG Americas Securities LLC purchased a new position in Capricor Therapeutics in the third quarter worth approximately $133,000. Rhumbline Advisers purchased a new stake in Capricor Therapeutics in the second quarter valued at $147,000. The Manufacturers Life Insurance Company acquired a new position in shares of Capricor Therapeutics in the 3rd quarter valued at $161,000. Finally, Sassicaia Capital Advisers LLC purchased a new position in shares of Capricor Therapeutics during the 3rd quarter worth $192,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Oppenheimer restated an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research report on Monday, September 23rd. HC Wainwright restated a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a report on Thursday, November 14th. Maxim Group upped their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Piper Sandler assumed coverage on shares of Capricor Therapeutics in a research report on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price for the company. Finally, Cantor Fitzgerald boosted their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.